Condition
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 2 (1)
Trial Status
Recruiting2
Active Not Recruiting1
Unknown1
Clinical Trials (4)
Showing 4 of 4 trials
NCT04619004Phase 2Active Not Recruiting
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
NCT04216121RecruitingPrimary
LAT for Oligoprogressive NSCLC Treated With First-line OSImertinib
NCT06207292Not ApplicableUnknown
Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer
NCT06102928Not ApplicableRecruitingPrimary
A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation
Showing all 4 trials